Posibles efectos adversos del tratamiento supresor de la TSH en el carcinoma diferenciado de tiroides

Sánchez Franco, 2005, Directrices para el tratamiento del carcinoma diferenciado de tiroides, Endocrinol Nutr., 52, 23 Pacini, 2006, European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium, Eur J Endocrinol., 154, 787, 10.1530/eje.1.02158 Cooper, 2009, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer, Thyroid., 19, 1167, 10.1089/thy.2009.0110 Hay, 2002, Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients, World J Surg., 26, 879, 10.1007/s00268-002-6612-1 Mandel, 1993, Levothyroxine therapy in patients with thyroid disease, Ann Intern Med., 119, 492, 10.7326/0003-4819-119-6-199309150-00009 Biondi, 2005, Thyroid-hormone therapy and thyroid cancer: a reassessment, Nat Clin Pract Endocrinol Metab., 1, 32, 10.1038/ncpendmet0020 Dunhill, 1937, Surgery of the thyroid gland (The Lettsomian Lectures), BMJ., 1, 460, 10.1136/bmj.1.3973.460 Balme, 1954, Metastastic carcinoma of the thyroid successfully treated with thyroxine, Lancet., 266, 812, 10.1016/S0140-6736(54)91480-4 Crile, 1966, Endocrine dependency of papillary carcinomas of the thyroid, JAMA, 195, 721, 10.1001/jama.1966.03100090055013 Goldberg, 1981, Thyroid carcinoma with spinal cord compression, JAMA., 245, 953, 10.1001/jama.1981.03310340043025 Mazzaferri, 1994, Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer, Am J Med., 97, 418, 10.1016/0002-9343(94)90321-2 Pujol, 1996, Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer, J Clin Endocrinol Metab., 81, 4318, 10.1210/jc.81.12.4318 Cooper, 1998, Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry, Thyroid., 8, 737, 10.1089/thy.1998.8.737 Nadler, 1970, The effect of hypophysectomy on the experimental production of rat thyroid neoplasms, Cancer Res., 30, 1909 Ichikawa, 1976, Presence of TSH receptor in thyroid neoplasms, J Clin Endocrinol Metab., 42, 395, 10.1210/jcem-42-2-395 Clark, 1983, Characterization of the thyrotropin receptor-adenylate cyclase system in neoplastic human thyroid tissue, J Clin Endocrinol Metab., 57, 140, 10.1210/jcem-57-1-140 Lazar, 1999, Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes, J Clin Endocrinol Metab., 84, 3228, 10.1210/jc.84.9.3228 Filetti, 1999, Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism, Eur J Endocrinol., 14, 443, 10.1530/eje.0.1410443 Westermark, 1983, Epidermal growth factor modulates thyroid growth and function in culture, Endocrinology., 112, 1680, 10.1210/endo-112-5-1680 Fagin, 2004, How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy, J Endocrinol., 183, 249, 10.1677/joe.1.05895 Riesco-Eizaguirre, 2007, Molecular biology of thyroid cancer initiation, Clin Transl Oncol., 9, 686, 10.1007/s12094-007-0125-1 Burmeister, 1992, Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer, J Clin Endocrinol Metab., 75, 344, 10.1210/jc.75.2.344 Sawin, 1989, The aging thyroid. The use of thyroid hormone in older persons, JAMA., 261, 2653, 10.1001/jama.1989.03420180077034 Andersen, 2002, Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease, J Clin Endocrinol Metab., 87, 1068, 10.1210/jc.87.3.1068 Goichot, 2009, Subclnical hyperthyroidism: Considerations in defining the lower limit of the thyrotropin reference interval, Clin Chem., 55, 420, 10.1373/clinchem.2008.110627 Biondi, 2008, The clinical significance of subclinical thyroid dysfunction, Endocr Rev., 29, 76, 10.1210/er.2006-0043 Reverter, 2007, Cáncer de tiroides, levotiroxina y masa ósea. La evidencia, la experiencia y tres preguntas, Endocrinol Nutr., 54, 237, 10.1016/S1575-0922(07)71441-9 Klein, 2001, Thyroid hormone and the cardiovascular system, N Engl J Med., 344, 501, 10.1056/NEJM200102153440707 Fazio, 2004, Effects of thyroid hormone on the cardiovascular system, Recent Prog Horm Res., 59, 31, 10.1210/rp.59.1.31 Murphy, 2004, The thyroid and the skeleton, Clin Endocrinol (Oxf)., 61, 285, 10.1111/j.1365-2265.2004.02053.x Reverter, 2005, Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma, Endocr Relat Cancer., 12, 973, 10.1677/erc.1.01072 Reverter, 2010, Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma, Endocrine., 37, 467, 10.1007/s12020-010-9339-z Heemstra, 2006, The effects of thyrotropinsuppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma, Thyroid., 16, 583, 10.1089/thy.2006.16.583 van der Cammen, 2003, Lack of association between thyroid disorders and Alzheimer's disease in older persons: a crosssectional observational study in a geriatric outpatient population, J Am Geriatr Soc., 51, 884, 10.1046/j.1365-2389.2003.51278.x Kalmijn, 2000, Subclinical hyperthyroidism and the risk of dementia. The Rotterdam Study, Clin Endocrinol (Oxf)., 53, 733, 10.1046/j.1365-2265.2000.01146.x Eustatia-Rutten, 2006, Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial, Clin Endocrinol (Oxf)., 64, 284, 10.1111/j.1365-2265.2006.02458.x Eustatia-Rutten, 2008, Autonomic nervous system function in chronic exogenous subclinical thyrotoxicosis and the effect of restoring euthyroidism, J Clin Endocrinol Metab., 93, 2835, 10.1210/jc.2008-0080 Botella-Carretero, 2006, Effects of thyroid hormones on serum levels of adipokines as studied in patients with differentiated thyroid carcinoma during thyroxine withdrawal, Thyroid., 16, 397, 10.1089/thy.2006.16.397 Horne, 2004, Is thyroid hormone suppression therapy prothrombotic? J Clin Endocrinol Metab., 89, 4469, 10.1210/jc.2004-0536 Brabant, 2008, Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets?, J Clin Endocrinol Metab., 93, 1167, 10.1210/jc.2007-2228 Surks, 2004, Subclinical thyroid disease: scientific review and guidelines for diagnosis and management, JAMA., 291, 228, 10.1001/jama.291.2.228 Klein, 2001, Thyroid hormone: targeting the vascular smooth muscle cell, Circ Res., 88, 260, 10.1161/01.RES.88.3.260 Parry CH. Elargement of thyroid gland in connection with enlargement or palpitation of the heart. Collection from unpublished papers of the late Caleb Hillier Parry. London: Welcome Library for the History and Understanding of Medicine; 1825. p. 111–25. Boelaert, 2005, Thyroid hormone in health and disease, J Endocrinol., 187, 1, 10.1677/joe.1.06131 Biondi, 1993, Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine, J Clin Endocrinol Metab., 77, 334, 10.1210/jc.77.2.334 Biondi, 1999, Effects of chronic subclinical hyperthyroidism from levothyroxine on cardiac morphology and function, Cardiologia., 44, 443 Shapiro, 1997, Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine, J Clin Endocrinol Metab., 82, 2592, 10.1210/jc.82.8.2592 Ching, 1996, Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis, Heart., 75, 363, 10.1136/hrt.75.4.363 Mercuro, 2000, Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring, J Clin Endocrinol Metab., 85, 159, 10.1210/jc.85.1.159 Gullu, 2004, Effects of TSH-suppressive therapy on cardiac morphology and function: beneficial effects of the addition of betablockade on diastolic dysfunction, Eur J Endocrinol., 150, 655, 10.1530/eje.0.1500655 Smit, 2005, Reversible diastolic dysfunction alter long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study, J Clin Endocrinol Metab., 90, 6041, 10.1210/jc.2005-0620 Shargorodsky, 2006, Longterm thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma, Thyroid., 16, 381, 10.1089/thy.2006.16.381 Botella-Carretero, 2004, Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma, Endocr Relat Cancer., 11, 345, 10.1677/erc.0.0110345 Sawin, 1994, Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons, Engl J Med., 331, 1249, 10.1056/NEJM199411103311901 Auer, 2001, Subclinical hyperthyroidism as a risk factor for atrial fibrillation, Am Heart J., 142, 838, 10.1067/mhj.2001.119370 Cappola, 2006, Thyroid status, cardiovascular risk, and mortality in older adults, JAMA., 295, 1033, 10.1001/jama.295.9.1033 Parle, 2001, Prediction of allcause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study, Lancet., 358, 861, 10.1016/S0140-6736(01)06067-6 Gussekloo, 2004, Thyroid status, disability and cognitive function, and survival in old age, JAMA., 292, 2591, 10.1001/jama.292.21.2591 van den Beld, 2005, Thyroid hormone concentrations, disease, physical function, and mortality in elderly men, J Clin Endocrinol Metab., 90, 6403, 10.1210/jc.2005-0872 Walsh, 2005, Subclinical thyroid dysfunction as a risk factor for cardiovascular disease, Arch Intern Med., 165, 2467, 10.1001/archinte.165.21.2467 Singh, 2008, Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis, Int J Cardiol., 125, 41, 10.1016/j.ijcard.2007.02.027 Flynn, 2010, Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy, J Clin Endocrinol Metab., 95, 186, 10.1210/jc.2009-1625 Bauer, 2007, Thyroid hormone use, hyperthyroidism and mortality in older women, Am J Med., 120, 343, 10.1016/j.amjmed.2006.04.034 Links, 2005, Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis, Endocr Relat Cancer., 12, 273, 10.1677/erc.1.00892 Eustatia-Rutten, 2006, Survival and death causes in differentiated thyroid carcinoma, J Clin Endocrinol Metab., 91, 313, 10.1210/jc.2005-1322 Biondi, 2010, Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer, Thyroid., 20, 135, 10.1089/thy.2009.0311 Christ-Crain, 2005, Pro-A-type and N-terminal pro-B-type natriuretic peptides in different thyroid function states, Swiss Med Wkly., 135, 549 Von Recklinhausen F. Die fibrose oder deformiedere ostitis, die osteomalazie und die osteoplastische karzinose in ihren gegenseitigen beziehungen. In: Festschrift Rudolf Virchow. Berlin: George Reimer; 1 1891. Bassett, 2003, The molecular actions of thyroid hormone in bone, Trends Endocrinol Metab., 14, 356, 10.1016/S1043-2760(03)00144-9 Abe, 2003, TSH is a negative regulator of skeletal remodeling, Cell., 115, 151, 10.1016/S0092-8674(03)00771-2 Mosekilde, 1990, Effects of thyroid hormones on bone and mineral metabolism, Endocrinol Metab Clin North Am., 19, 35, 10.1016/S0889-8529(18)30338-4 Eriksen, 1985, Trabecular bone remodeling and bone balance in hyperthyroidism, Bone., 6, 421, 10.1016/8756-3282(85)90218-2 Rosen, 1992, Longitudinal changes in lumbar bone density hmong thyrotoxic patients after attainment of euthyroidism, Clin Endocrinol Metab., 75, 1531, 10.1210/jc.75.6.1531 Vestergaard, 2000, Fracture risk in patients treated for hyperthyroidism, Thyroid., 10, 341, 10.1089/thy.2000.10.341 Karga, 2004, Bone mineral density in hyperthyroidism, Clin Endocrinol (Oxf)., 61, 466, 10.1111/j.1365-2265.2004.02110.x Görres, 1996, Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated thyroid carcinoma, Eur J Nucl Med., 23, 690, 10.1007/BF00834532 Giannini, 1994, Bone density and mineral metabolism in thyroidectomized patients treated with long-term L-thyroxine, Clin Sci (Lond)., 87, 593, 10.1042/cs0870593 Franklyn, 1992, Long-term thyroxine treatment and bone mineral density, Lancet., 4, 9, 10.1016/0140-6736(92)92423-D Lehmke, 1992, Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in postmenopausal women, Clin Endocrinol (Oxf)., 36, 511, 10.1111/j.1365-2265.1992.tb02254.x Ribot, 1990, Bone mineral density and thyroid hormone therapy, Clin Endocrinol (Oxf)., 33, 143, 10.1111/j.1365-2265.1990.tb00477.x Diamond, 1991, A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma, J Clin Endocrinol Metab., 72, 1184, 10.1210/jcem-72-6-1184 Paul, 1988, Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women, JAMA., 259, 10.1001/jama.1988.03720210027023 Hawkins, 1994, Spinal bone mass after longterm treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis, Calcif Tissue Int., 54, 16, 10.1007/BF00316283 Rosen, 1998, Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate, J Clin Endocrinol Metab., 83, 2324, 10.1210/jc.83.7.2324 Jódar, 1998, Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass, Osteoporosis Int., 8, 311, 10.1007/s001980050069 Kung, 1996, Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin, J Clin Endocrinol Metab., 81, 1232, 10.1210/jc.81.3.1232 Pioli, 1992, Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women, Acta Endocrinol (Copenh)., 126, 238, 10.1530/acta.0.1260238 McDermott, 1995, A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer, Calcif Tissue Int., 56, 521, 10.1007/BF00298581 Faber, 1994, Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis, Eur J Endocrinol., 130, 350, 10.1530/eje.0.1300350 Uzzan, 1996, Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis, J Clin Endocrinol Metab., 81, 4278, 10.1210/jc.81.12.4278 Schneider, 2003, The effect of levothyroxine therapy on bone mineral density: a systematic review of the literature, Exp Clin Endocrinol Diabetes., 111, 455, 10.1055/s-2003-44704 Bauer, 2001, Risk for fracture in women with low serum levels of thyroidstimulating hormone, Ann Intern Med., 134, 561, 10.7326/0003-4819-134-7-200104030-00009 Bauer, 1997, Low thyrotropin levels are not associated with bone loss in older women: a prospective study, J Clin Endocrinol Metab., 82, 2931, 10.1210/jc.82.9.2931 Leese, 1992, Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH, Clin Endocrinol (Oxf)., 37, 500, 10.1111/j.1365-2265.1992.tb01480.x Grabe, 2005, Mental and physical complaints in thyroid disorders in the general population, Acta Psychiatr Scand., 112, 286, 10.1111/j.1600-0447.2005.00586.x Larisch, 2004, Depression and anxiety in different thyroid function states, Horm Metab Res., 36, 650, 10.1055/s-2004-825925 Botella-Carretero, 2003, Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma, Endocr Relat Cancer., 10, 601, 10.1677/erc.0.0100601 Tagay, 2005, Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment, Eur J Endocrinol., 153, 755, 10.1530/eje.1.02047 Squizzato, 2007, Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review, J Clin Endocrinol Metab., 92, 2415, 10.1210/jc.2007-0199 Botella-Carretero, 2005, The effects of thyroid hormones on circulating markers of cellmediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal, Eur J Endocrinol., 153, 223, 10.1530/eje.1.01951 Reverter, 2010, Clinical endocrinologists’ perception of the deleterious effects of TSH suppressive therapy in patients with differentiated thyroid carcinoma. [Article in Spanish], Endocrinol Nutr., 57, 350, 10.1016/j.endonu.2010.03.015 Mazzaferri, 2002, Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin, Endocr Relat Cancer., 9, 227, 10.1677/erc.0.0090227 Hundahl, 2000, Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U. S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study, Cancer., 89, 202, 10.1002/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-A Jonklaas, 2006, Outcomes of patients with differentiated thyroid carcinoma following initial therapy, Thyroid., 16, 1229, 10.1089/thy.2006.16.1229 Cooper, 2010, TSH suppressive therapy: an overview of long-term clinical consequences, Hormones (Athens)., 9, 57, 10.14310/horm.2002.1259 Lameloise, 2001, Differences between the effects of thyroxine and tetraiodothyroacetic acid on TSH suppression and cardiac hypertrophy, Eur J Endocrinol., 144, 145, 10.1530/eje.0.1440145 Sherman, 1999, Central hypothyroidism associated with retinoid X receptor-selective ligands, N Engl J Med., 340, 1075, 10.1056/NEJM199904083401404 Galofré, 2010, Manejo del cáncer de tiroides en España, Endocrinol Nutr. Endocrinol Nutr., 57, 347, 10.1016/j.endonu.2010.06.006